ANUH PHARMA LIMITED

The investor presentation for Q1 FY 2026-27 reported that Anuh Pharma Limited achieved an operating revenue of Rs. 193.81 crores, reflecting a 3.93% year-over-year increase. EBITDA rose by 41.56% to Rs. 19.36 crores, with a margin improvement to 9.99%. Profit After Tax (PAT) was reported at Rs. 11.42 crores, up 37.63% year-over-year, resulting in an EPS of Rs. 1.14. The company highlighted a production increase of 19.46% to 491 MT. Management attributed the profit growth to a richer product mix, disciplined cost control, and enhanced throughput from existing assets. The presentation also outlined future growth strategies, including volume expansions and market diversification, with a goal of achieving a steady growth rate of 15-20% per annum. Anuh Pharma emphasized its commitment to sustainable growth and corporate social responsibility initiatives.

Management emphasized strong financial performance and growth strategies.